Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say

Incyte (INCY) reported $1.18 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 16.3%. EPS of $1.43 for the same period compares to $1.06 a year ago.The reported revenue represents a surprise of +2.63% over the Zacks Consensus Estimate of $1.15 billion. With the consensus EPS estimate being $1.53, the EPS surprise was -6.54%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Incyte performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product royalty revenues: $159.29 million versus the nine-analyst average estimate of $161.69 million. The reported number represents a year-over-year change of +6.5%. Net product revenues- Iclusig: $27.37 million compared to the $29.69 million average estimate based on nine analysts. The reported number represents a change of +0.9% year over year. Net product revenues- Pemazyre: $23.14 million versus the nine-analyst average estimate of $19.08 million. The reported number represents a year-over-year change of +12.1%. Net product revenues- Minjuvi/ Monjuvi: $32.81 million versus $33.75 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +264.8% change. Net product revenues- Opzelura: $161.60 million versus $150.33 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +47.9% change. Net product revenues- Jakafi: $773.11 million versus the nine-analyst average estimate of $745.88 million. The reported number represents a year-over-year change of +11.2%. Net product revenues- Zynyz: $1.37 million versus the nine-analyst average estimate of $0.96 million. Revenues- Product revenues: $1.02 billion compared to the $999.96 million average estimate based on nine analysts. The reported number represents a change of +18.3% year over year. Royalty revenues- Olumiant: $38.49 million versus $39.58 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -4.6% change. Royalty revenues- Tabrecta: $6.29 million compared to the $6.27 million average estimate based on eight analysts. The reported number represents a change of +34.4% year over year. Royalty revenues- Jakavi: $114.19 million versus $116.30 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +9.9% change. Royalty revenues- Pemazyre: $0.33 million versus $0.67 million estimated by seven analysts on average. View all Key Company Metrics for Incyte here>>>Shares of Incyte have returned +5.1% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Incyte Corporation (INCY): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks